Tumor-induced osteomalacia (TIO) is an ultrarare paraneoplastic syndrome due to
overproduction of fibroblast growth factor 23 (FGF23), with profound effects on patient …

Approximately 15% of lung cancer cases are of the small cell subtype, but this variant is
highly aggressive and is often diagnosed at advanced stages. Outcomes after current …

Context: Oncogenic osteomalacia, a paraneoplastic syndrome associated with
hypophosphatemia due to increased urinary phosphate excretion, is caused by excessive …

Background Tumor‐induced osteomalacia (TIO) belongs to a rare disease of the
paraneoplastic syndrome. Phosphate uric mesenchymal tumor (PMT) is the most common …

Tumor-induced osteomalacia (TIO) is typically caused by phosphaturic mesenchymal tumor
(PMT) that secretes the phosphaturic hormone, fibroblast growth factor-23 (FGF23), resulting …

Although there are a few case reports of patients with small cell lung cancer developing
hypophosphatemia, detailed information on this condition is scarce. A 52-year-old patient …

Purpose Tumor-induced osteomalacia (TIO) is rare paraneoplastic disorder generally
caused by small benign neoplasm. Somatostatin receptor imaging has emerged as imaging …

The use of computerized tomography (CT) scans has been recently brought into attention to
help screen high risk individuals for lung cancer. Even though they are highly sensitive, their …

Neoplasms that cause tumor-induced osteomalacia are very rarely located in the lung. A 27-
year-old man underwent a surgery in the right femoral head to remove the tumor that …

In recent years, the incidence of lung cancer (LC) has been increasing throughout the world
and is the most common type of cancer in all regions of the world, occurring more frequently …